Shattuck Shifts Gears After Lackluster CD47-Targeting Bispecific Results
The biotech is cutting jobs and discontinuing development of its anti-CD47 bispecific for blood cancers and moving its focus to SL-325, which targets the TL1A-DR3 axis in autoimmune diseases.
